Design Corp (DSGN): Debts to Book Capitalization

Corporate company logo of Design Pharma (DSGN)

Design Therapeutics is shielded from sanctions and political risks due to its localization within US hubs. Design Therapeutics sponsors scientific research on gene expression management in collaboration with universities for oncology therapy. The market trend for the share price, which currently stands at 0.01, highlights the potential for scaling treatment via outsourced production without capital expenditures on factories.

Design Therapeutics (DSGN) - Debts to Book Value from 07/04/2022 to 10/28/2026

Metric breakdowns and analytics for Design Therapeutics Inc (DSGN)

- price and consensus price forecast:
Stock Price Design Therapeutics|DSGN - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Design Corp|DSGN - Business Value
- book capitalization data:
Book Value per Share Design Therapeutics|DSGN - Total Stockholders' Equity|Market Value to Book Value Ratio designtx.com|DSGN - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital Design Therapeutics|DSGN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Design Pharma|DSGN - Company Total Indebtedness|Debt to Book Capitalization Ratio Design Corp|DSGN - Company Long-Term Indebtedness|Company Current Liabilities Design Therapeutics
Summary company analytics:DSGN - Design Therapeutics
Brand item of Design Therapeutics Inc

Design Therapeutics focuses on attracting niche drug safety experts, utilizing a stock option system to retain key scientific staff. This chart of the company's financial leverage trend allows for an assessment of the debt-to-equity ratio, helping investors filter out market noise and determine the actual level of debt risk within the business's financing structure.

Competitors of Design Therapeutics (DSGN)

Debts to Book Capitalization TEM (Tempus AI Inc)|Debts to Book Capitalization qiagen.com QGEN|Ionis (IONS) - Debts to Book Capitalization|RGEN - Debt to Book Value Ratio|Debts to Book Capitalization RNA|CRSP (CRISPR) - Debts to Book Value|WGS: Debt to Book Capitalization Ratio|Debts to Net Assets ultragenyx.com|BEAM (Beam Therapeutics) - Debts to Book Capitalization|Debts to Net Assets Sarepta Therapeutics (SRPT)|TWST (Twist Bio) - Debts to Book Capitalization|10x - Debt to Net Assets|Intellia Therapeutics (NTLA) - Debt to Book Capitalization Ratio|stoketherapeutics.com (STOK) - Debt to Book Value Ratio|Debt to Book Value BioLife Solutions BLFS|Debt to Net Assets Ratio Wave Life Sciences Ltd|Maze Tx (MAZE) - Debt to Book Value|Debt to Book Capital Sionna Corp|Prime Medicine, Inc. (PRME) - Debts to Book Capitalization|Debt to Net Assets Ratio tayshagtx.com (TSHA)|QURE: Debts to Book Capitalization|MeiraGTx Holdings - Debts to Book Value|Debt to Book Capitalization Ratio Regenxbio (RGNX)|SLDB - Debt to Net Assets Ratio|OCGN: Debts to Book Capitalization|PACB (pacb.com) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Benitec Biopharma BNTC|Debts to Book Capitalization Ratio Rocket Pharma|4D Molecular Therapeutics Inc - Debts to Book Capitalization|Debts to Book Value lexeotx.com LXEO|Debt to Book Value KRRO (Korro Bio)|EDIT - Debts to Book Capitalization|Debt to Book Value Silence Therapeutics plc SLN|PRQR - Debt to Book Capital|codexis.com - Debts to Book Capitalization|Sangamo BioSciences (SGMO) - Debts to Net Assets|Debts to Book Capitalization NAUT|Debt to Book Value MGX|DTIL (Precision BioSciences, Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets generationbio.com (GBIO)|BOLD - Debts to Book Capitalization|Exicure Inc. - Debt to Book Value Ratio|Debt to Book Capitalization Ratio IMNN (Celsion Corporation)|PHIO - Debts to Net Assets|Debts to Book Capitalization MBIO (mustangbio.com)|RNAZ (TransCode Therapeutics, Inc.) - Debt to Net Assets|Debt to Book Capitalization Ratio Bionano Genomics Inc. (BNGO)|Debt to Book Value Ratio Applied DNA Corp|Debts to Book Capitalization bluebird bio, Inc. BLUE|Debt to Book Value Ratio IPA (immunoprecise.com)|OMGA - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Singular Genomics Systems, Inc. OMIC|Regulus Therapeutics Inc - Debts to Book Capitalization|SYRS - Debts to Book Capitalization|Debts to Book Capitalization Telesis Bio, Inc.|traconpharma.com (TCON) - Debt to Book Value Ratio|Debts to Book Capitalization UBX (Unity Biotechnology, Inc.)